Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis

被引：13

作者：

Ikuma, Daiuske ^{[1
]}

Oguro, Masahiko ^{[1
]}

Hoshino, Junichi ^{[1
]}

Mizuno, Hiroki ^{[1
]}

Sekine, Akinari ^{[1
]}

Kawada, Masahiro ^{[1
]}

Hiramatsu, Rikako ^{[1
]}

Sumida, Keiichi ^{[1
]}

Hasegawa, Eiko ^{[1
]}

Hayami, Noriko ^{[1
]}

Yamanouchi, Masayuki ^{[1
]}

Suwabe, Tatsuya ^{[1
]}

Sawa, Naoki ^{[1
]}

Takaichi, Kenmei ^{[1
]}

Ubara, Yoshifumi ^{[1
]}

机构：

[1] Toranomon Gen Hosp, Nephrol Ctr, 2-2-2 Minato Ku, Tokyo 1050001, Japan

来源：

CEN CASE REPORTS | 2020年 / 9卷 / 01期

关键词：

Plaque psoriasis; Secukinumab; Hemodialysis and end stage renal disease (ESRD); ADALIMUMAB TREATMENT; JAPANESE PATIENTS; ARTHRITIS; SAFETY; ETANERCEPT; MODERATE; THERAPY;

D O I：

10.1007/s13730-019-00426-z

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Secukinumab is effective to treat plaque psoriasis. However, the safety and efficiency of secukinumab have not been clarified in patients on hemodialysis. We report a 60-year-old Japanese woman. Plaque psoriasis was diagnosed at the age of 25 years and hemodialysis was started at the age of 39 years. Her skin lesions persisted despite use of topical agents such as maxacalcitol and betamethasone. Accordingly, administration of secukinumab was started at a dose of 150 mg. The psoriasis area and severity index (PASI) score decreased from 49.8 to 14.8 after 2 weeks and to 0 after 6 weeks, with remission being maintained after 28 months. No adverse reactions were seen. This case indicates that secukinumab may be effective for severe psoriasis in patients on hemodialysis for end-stage renal disease.

引用

页码：55 / 58

页数：4

共 16 条

[1] Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study [J].

Asahina, Akihiko ;

Nakagawa, Hidemi ;

Etoh, Takafumi ;

Ohtsuki, Mamitaro .

JOURNAL OF DERMATOLOGY, 2010, 37 (04) :299-310

[2] Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection [J].

Cassano, Nicoletta ;

Vena, Gino A. .

INTERNATIONAL JOURNAL OF DERMATOLOGY, 2008, 47 (09) :980-981

[3] The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis [J].

Don, BR ;

Spin, G ;

Nestorov, I ;

Hutmacher, M ;

Rose, A ;

Kaysen, GA .

JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (11) :1407-1413

[4] SEVERE PSORIASIS - ORAL THERAPY WITH A NEW RETINOID [J].

FREDRIKSSON, T ;

PETTERSSON, U .

DERMATOLOGICA, 1978, 157 (04) :238-244

[5] Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial [J].

Igarashi, Atsuyuki ;

Kato, Takeshi ;

Kato, Mai ;

Song, Michael ;

Nakagawa, Hidemi .

JOURNAL OF DERMATOLOGY, 2012, 39 (03) :242-252

[6] Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure [J].

Kusakari, Yoshiyuki ;

Yamasaki, Kenshi ;

Takahashi, Toshiya ;

Tsuchiyama, Kenichiro ;

Shimada-Omori, Ryoko ;

Nasu-Tamabuchi, Mei ;

Aiba, Setsuya .

JOURNAL OF DERMATOLOGY, 2015, 42 (07) :727-730

[7] Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis [J].

Mease, Philip J. .

CURRENT OPINION IN RHEUMATOLOGY, 2015, 27 (02) :127-133

[8] Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study [J].

Ohtsuki, Mamitaro ;

Morita, Akimichi ;

Abe, Masatoshi ;

Takahashi, Hidetoshi ;

Seko, Noriko ;

Karpov, Alexander ;

Shima, Tomohiro ;

Papavassilis, Charis ;

Nakagawa, Hidemi .

JOURNAL OF DERMATOLOGY, 2014, 41 (12) :1039-1046

[9] Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE) [J].

Paul, C. ;

Lacour, J. -P. ;

Tedremets, L. ;

Kreutzer, K. ;

Jazayeri, S. ;

Adams, S. ;

Guindon, C. ;

You, R. ;

Papavassilis, C. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (06) :1082-1090

[10] Profile of secukinumab in the treatment of psoriasis: current perspectives [J].

Roman, Michael ;

Madkan, Vandana K. ;

Chiu, Melvin W. .

THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 :1767-1777

← 1 2 →